Emergent BioSolutions awarded $30M BARDA contract modification for CYFENDUS anthrax vaccine

Emergent BioSolutions Inc.

Modification No. 20 valued at $30M for additional doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted).
Deliveries begin calendar 2025 and are scheduled to be completed by March 2026.
Follows a prior $50M modification in December 2024 for the same vaccine.
CYFENDUS received FDA approval in July 2023 as a two-dose post-exposure prophylaxis for adults 18-65.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.